DiaMedica‘s Phase I/II trial of DM199 in Type 2 diabetic patients reached its primary clinical endpoints of demonstrating its safety, tolerability and sustained pharmacokinetic (PK) properties, while also suggesting an insulin sensitization mechanism of action for Type 2 diabetes. The randomized, double-blinded, placebo-controlled study enrolled 10 Type 2 diabetic patients. The patients were dosed with either DM199 at three single ascending dose levels or placebo. DM199 was well-tolerated...